Free Trial
→ Important SpaceX PREDICTION (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q3 2024 Earnings Report

Innoviva logo
$22.52 0.00 (0.00%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$22.52 +0.00 (+0.02%)
As of 06/5/2026 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
$0.02
Consensus EPS
$0.27
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$89.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q3 2024
Date
11/6/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 5, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Innoviva's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, July 30, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q3 2024 Press ReleasePress Release
(8-K)
Innoviva's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Innoviva Earnings Headlines

Innoviva, Inc. (NASDAQ:INVA) Given Average Recommendation of "Moderate Buy" by Brokerages
June 7 at 4:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30824696
Wall Street Zen Upgrades Innoviva (NASDAQ:INVA) to Buy
June 6 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30821903
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst environment in 50 years - with portfolios potentially staying in the red for 10 years or longer. From rate spikes in 2022 to $12 trillion wiped out in 30 days during the Iran War, Wall Street suggests the volatility isn't slowing down. TradeSmith CEO Keith Kaplan is showing investors what steps to take now to prepare their wealth before this worsens.tc pixel
 |  TradeSmith (Ad)
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
May 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/motley/2209825/innoviva-stock-is-up-just-10-this-past-year-here-s-why-a-fund-bought-2-5-million-more/
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/theravance-biopharma-solid-1q26-execution-cost-cuts-and-yupelri-momentum-drive-buy-rating-and-price-target-increase-to-19-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?
May 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/innoviva-inva-pricing-look-compelling-100809040.html
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools